While more firms got money, fewer dollars were shelled outMONEY TREE – The dollar amount of deals dropped between the third and fourth quarters of 2006, but Q4 still saw a healthy jump in the number of companies that hooked up with venture funds.
According to The MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association based on data from Thomson Financial, 23 Garden State companies received $176.4 million in funding in the fourth quarter of 2006. In the previous quarter, 16 companies had taken in $226 million. To put the year in perspective, the MoneyTree Report shows that most investment activity took place in the second and third quarters.
The recipient of the most funding in the last quarter was Home Décor Products in Edison. It got $65 million, representing 36.75 percent of all the financing in New Jersey for the period.
For the full year, 80 funding deals in the state brought in some $757 million. That compares with 78 local deals signed in 2005 worth $833.7 million. According to the report, the nation saw investing dollars increase by 11.8 percent to $25.5 billion last year compared with 2005.
ÂCommunications showed signs of life while software/IT continued to be strong. In health care and life sciences, the region continues to produce a lot of early-stage companies, with therapeutics, medical devices and specialty pharma commanding most of the attention, says Phillip P. Chan, partner with the NJTC Venture Fund in Mount Laurel. ÂHowever, interest in diagnostics is starting to return as venture investors realize diagnosis and treatment go hand in hand.Â
Local life sciences and consumer-products firms got the most attention from investors in the fourth quarter. Ten local companies in the life sciences sector received a total of $73 million for the period. Meanwhile, two consumer-products companies, including Home Décor Products, garnered a collective $73.4 million.
E-mail to [email protected]
AkaRx
Investment: $2 million
Mack Centre IV, Fourth Floor
South 61 Paramus Road
Paramus 07652
Phone: (201) 909-3000
Fax: (201) 909-3004
URL: www.akarx.com
Third round of funding for this developer of cancer and hematology products.
Amorcyte
Investment: NA
21 Main St.
Court Plaza South, East Wing, Suite 34
Hackensack 07601
Phone: (201) 883-5314
This was the second round of funding for this biotechnology firm that develops cell-based therapies for cardiovascular diseases.
aTyr Pharma
Investment: $10.5 million
221 Nassau St.
Princeton 08542-4601
Phone: (609) 924-6422
Second round of funding for the start-up biopharmaceutical company develops novel protein biologics for regenerative medicine.
AvePoint
370 Campus Drive, Suite 104
Somerset 08873
Phone: (732) 271-8688
Fax: (732) 271-8655
URL: www.avepoint.com
First round of funding for the early-stage software company that provides backup and data-management solutions.
Billtrust
Investment: $4 million
1095 Cranbury-South River Road, Suite 3
Jamesburg 08831-3411
Phone: (609) 235-1010
Fax: (609) 235-1011
URL: www.billtrust.com
First round of financing for Billtrust, which provides outsourced billing services.
Blue Tulip
Investment: $7 million
Princeton 08540
Phone: (609) 375-2000
URL: www.bluetulip.com
Second round of funding for this early-stage company that operates a chain of 17 stores specializing in personalized gifts.
CircuLite
Investment: $10.2 million
Hackensack
Phone: (201) 487-1005
URL: www.CircuLite.net
Third round of funding for this early-stage developer of implantable medical devices for treating serious heart conditions.
EKR Therapeutics
Investment: $2.3 million
7 E. Frederick Place
Cedar Knolls 07927
Phone: (877) 435-2524
URL: www.ekrtx.com
Second round of funding for this early-stage company that develops products to help oncology patients manage their symptoms.
First Index Group
Investment: $500,000
99 Cherry Hill Road, Suite 210
Parsippany 07054-1102
Phone: (973) 331-2600
Sixth round of funding for the late-stage company that provides a Web-based platform that connects makers and buyers of custom-manufactured parts.
Home Décor Products
Investment: $65 million
47 Brunswick Ave.
Edison 08817
Phone: (732) 593-1200
Fax: (732) 512-0691
URL: www.hdpi.com/
Fifth round of funding for this expansion-stage operator of Internet sites for the sale of kitchen and bath products, appliances and other home products.
IntegriChain
Investment: $2 million
100 Canal Pointe Blvd. Suite 210
Princeton 08540
Phone: (609) 806-5005
Fax: (609) 806-5006
URL: www.integrichain.com
First round of funding for this early-stage company that provides intelligence to prevent fraud in the supply chain for the life sciences industry.
IPP of America
Investment: $1.5 million
330 Passaic Ave., Suite 1
Fairfield 07004
Phone: (973) 830-1575
Fax: (973) 830-1576
URL: www.ipppays.com
Third round of funding for the expansion-stage company that runs an independent network of neighborhood-based payment centers for utilities, telecommunications providers and other billers.
The Janis Group
Investment: $750,000
201 W. Passaic St.
Rochelle Park 07662
Phone: (201) 291-5144
URL: www.jginfo.com
Fourth round of financing for this later-stage company, formerly known as Software Plus, that specializes in supply chain, human resources and payroll systems software.
Lamina Ceramics
Investment: $2 million
120 Hancock Lane
Westampton 08060
Phone: (609) 265-1401
Fax: (609) 265-9905
URL: www.laminaceramics.com
Ninth round of funding for the later-stage company that develops and manufactures super-bright LED arrays.
Lux Biosciences
Investment: $18 million
Harborside Financial Center Plaza 10, 14th Floor
(3 Second St., 14th Floor)
Jersey City 07302
Phone: (201) 344-7638
Fax: (201) 946-0552
URL: www.luxbio.com
Third round of financing for the early-stage biotech company that is developing medication to treat the underlying causes of eye diseases and alleviate their symptoms.
The Natural Dentist
Investment: $8.4 million
140 Sylvan Ave.
Englewood Cliffs 07632
Phone: (800) 615-6895
Fax: (201) 944-1717
URL: www.thenaturaldentist.com
First round of funding for the early-stage consumer-products company that makes an oral rinse to improve oral health and prevent oral bacteria from contributing to other health problems such as heart disease, stroke, diabetes and complications of pregnancy.
Onconova Therapeutics
Investment: $2.08 million
993 Lenox Drive, Suite 200
Lawrenceville 08648
Phone: (609) 844-7735
Fax: (609) 844-7736
URL: www.onconova.com
Fifth round of funding for this later-stage biopharmaceutical company that seeks to develop products for treating cancer by combining conventional pharmaceutical science with the latest genomic and genetic technologies for drug discovery and development.
Origin Digital
Investment: $5.5 million
Union City
Phone: (201) 272-8368
First round of funding for this early-stage, technology-based multimedia service provider.
Orthocon
Investment: $2.9 million
167 Stone Hill Road
Colts Neck 07722
Phone: (732) 683-9304
Fax: (732) 683-9476
URL: www.orthocon.com
Second round of financing for the medical and pharmaceutical device company working on products for the orthopedic- and spine-surgery markets.
ReGen Biologics
Investment: $5 million
509 Commerce St., East Wing
Franklin Lakes 07417
Phone: (201) 651-5140
Fax: (201) 651-5141
URL: www.regenbio.com
Fourth round of financing for the orthopedics-products company that develops, manufactures and markets innovative tissue-growth and repair products.
Scivantage
Investment: $6.76 million
10 Exchange Place, 13th Floor
Jersey City 07302
Phone: (646) 452-0050
URL: www.scivantage.com
First round of financing for the brokerage technology vendor that provides a range of products and services for investors and professional brokerages.
TotalStone
Investment: NA
Millstone
First round of financing for TotalStone, a distributor of Owens Corning Cultured Stone, a light-weight molded concrete product that imitates the physical appearance of natural stone.
VaxInnate
Investment: $20 million
3 Cedar Brook Drive
Cranbury 08512
Phone: (609) 860-2260
Fax: (609) 860-2290
URL: www.vaxinnate.com
Third round of financing for the biotechnology company that develops proprietary vaccines for both pandemic and seasonal influenza.
NA: not available